Positive Clinical Trial Results, Patient Enrollment, and Collaborations - Research Report on Pfizer, Medivation, AbbVie, Cigna, and AstraZeneca

Mon Oct 28, 2013 9:02am EDT

* Reuters is not responsible for the content in this press release.

Positive Clinical Trial Results, Patient Enrollment, and Collaborations - Research Report on Pfizer, Medivation, AbbVie, Cigna, and AstraZeneca

PR Newswire

NEW YORK, October 28, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Analysts' Corner announced new research reports highlighting Pfizer Inc. (NYSE: PFE), Medivation Inc. (NASDAQ: MDVN), AbbVie Inc. (NYSE: ABBV), AstraZeneca plc (ADR) (NYSE: AZN), and Cigna Corporation (NYSE: CI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Pfizer Inc. Research Report

On October 22, 2013, Pfizer Inc. (Pfizer) announced that after achieving technical milestones related to manufacturing, it will continue the development program for Remoxy (oxycodone) Extended-Release Capsules CII. Pfizer will proceed with the additional clinical studies and other actions required to address the Complete Response Letter received in June 2011. The Company confirmed that this comes after the guidance received from the U.S. Food and Drug Administration in early 2013. The Company said that the new clinical studies will include, in part, a pivotal bioequivalence study with the modified Remoxy formulation to bridge to the clinical data related to the original Remoxy formulation, as well as an abuse-potential study with modified formulation. The Company said that it does not expect the complete response submission to occur prior to mid-2015. Pfizer obtained rights to Remoxy in February 2011 as part of its acquisition of King Pharmaceuticals, Inc., which has an agreement with Pain Therapeutics Inc. to develop and commercialize the drug. The Full Research Report on Pfizer Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/d702_PFE]


Medivation Inc. Research Report

On October 22, 2013, Medivation Inc. (Medivation) and Astellas Pharma Inc. (Astellas) announced that the Independent Data Monitoring Committee (IDMC) informed the Companies of positive results from a planned interim analysis of the global Phase 3 PREVAIL trial of enzalutamide in more than 1,700 men with metastatic prostate cancer that has progressed despite androgen deprivation therapy and who have not yet received chemotherapy. Medivation said that the IDMC concluded that enzalutamide demonstrated a favorable benefit-risk ratio, given the observed benefits in the trial's co-primary endpoints of overall survival and radiographic progression-free survival, and considering the observed safety profile. Medivation further reported that the IDMC has recommended the study be stopped and patients treated with placebo be offered enzalutamide. Medivation and Astellas intend to begin meetings with and submissions to regulatory agencies starting early 2014. The Full Research Report on Medivation Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4277_MDVN]


AbbVie Inc. Research Report

On October 22, 2013, AbbVie Inc.'s (AbbVie) stock rose 1.34%, ending the day at $49.00, which is its highest closing price since the beginning of 2013. Over the previous three trading sessions, shares of AbbVie gained 1.72%, outperforming the S&P 500 which gained 1.24% during the same period. The Full Research Report on AbbVie Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/273c_ABBV]


AstraZeneca plc (ADR) Research Report

On October 22, 2013, AstraZeneca plc (ADR) (AstraZeneca) announced the first patient randomized in the Phase III clinical program for selumetinib, and oral, potent, selective MEK inhibitor, being investigated as second-line therapy in patients with advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors are KRAS mutation-positive. The Company said that the SELumetinib Evaluation as Combination Therapy-1 (SELECT-1) study is a randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of selumetinib plus docetaxel as a second line therapy in locally advanced or metastatic KRAS mutation-positive NSCLC. AstraZeneca expects the study to evaluate Progression Free Survival (PFS) and Overall Survival (OS). The Company reported that this will be the largest prospective study ever conducted in this patient population, a genetic subtype of lung cancer associated with poor prognosis and limited treatment options. AstraZeneca acquired exclusive worldwide rights to selumetinib from Array BioPharma in 2003. The Full Research Report on AstraZeneca plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7307_CI]


Cigna Corporation Research Report

On October 21, 2013, Cigna Corporation (Cigna), together with The Polyclinic, announced that the two Companies have launched a collaborative accountable care initiative to improve patient access to health care, enhance care coordination, and achieve the triple aim of improved health, affordability, and patient experience. The Company said that collaborative accountable care is part of its approach to accomplishing the same population health goals as accountable care organizations or ACOs. The program will benefit individuals covered by a Cigna health plan who receive care from The Polyclinic's 175 primary care doctors and specialists. Cigna added that it will compensate The Polyclinic for the medical and care coordination services it provides. Further, The Polyclinic may be rewarded through a "pay for value" structure if it meets targets for improving quality and lowering medical costs. The program became effective October 1, 2013 and is Cigna's second accountable care initiative in the Puget Sound area. The Full Research Report on Cigna Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/09cc_AZN]



  1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
  2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
  3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
  4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
  5. For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
  6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.


Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.


Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.


Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts' Corner

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.